My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Cadila Healthcare Ltd Research Report - 07th Nov 2016

Pharmaceutical | Published on Nov 07th 2016

IT

For 2QFY2017, Cadila Healthcare posted lower than expected results with sales at Rs2,336cr (vs. Rs2,737cr expected vs. Rs2,267cr in 2QFY2016), a yoy growth of 3.1%. On the operating front, the EBITDA margin came in at 21.4% (vs. 21.7% expected vs. 20.3% in 2QFY2016). The dip in the OPM was saved in spite of an underperformance on the sales front as the GPM improved to 63.9% (vs. 64.8% in 2QFY2016). The Adj. net profit came in at Rs338cr (vs. Rs461cr expected vs. Rs475cr in 2QFY2016), a yoy de-growth of 29.0%. We maintain our Neutral rating on the stock.

Download Full Report

Accumulate

CMP 390
Target Price
Investment Period12 Months

Stock Info

MCAP BSE (Rs in Cr)Array
MCAP NSE (Rs in Cr)Array
P/E (x)Array
EPS (Rs.)Array
BV (Rs.)Array
Div Yield (%)Array
FV (Rs.)Array
P/BV (x)Array
EV/Sales (x)Array
EV/EBITDA (x)Array

Shareholding Pattern (%)

Promoter75.0
Foreign10.0
Institution7.0
Public & Others6.0
Corporate2.0
Grand Total100.0

Trade Securely

AngelEye

Portfolio Tracking & Trading Application View Demo